Baseline characteristics of patients with CLL with and without MG
| Characteristics, n/N(%) . | M protein negative (N = 997) . | M protein positive (N = 226) . | P value . |
|---|---|---|---|
| Male | 643/997 (64.49) | 155/226 (68.58) | .244 |
| Age at diagnosis, median (SD) | 59.4 (10.43) | 60.19 (10.86) | .309 |
| Age > 65 years | 284/997 (28.49) | 69/226 (30.53) | .540 |
| Lymphadenopathy | 686/987 (69.50) | 143/223 (64.13) | .118 |
| Splenomegaly | 534/987 (54.10) | 167/223 (74.89) | <.001 |
| White blood cell count ≥100 × 109/L | 98/997 (9.83) | 21/226 (9.29) | .806 |
| Hemoglobin level <110 g/L | 209/997 (20.96) | 101/226 (44.69) | <.001 |
| Platelet count <100 × 109/L | 205/997 (20.56) | 66/226 (29.20) | .005 |
| Albumin <35 g/L | 34/962 (3.53) | 42/222 (18.92) | <.001 |
| Lactate dehydrogenase ≥248 U/L | 193/941 (20.51) | 76/214 (35.51) | <.001 |
| β2MG >3.5 mg/L | 270/865 (31.21) | 115/196 (58.67) | <.001 |
| Rai stage | <.001 | ||
| 0 | 138/997 (13.84) | 18/226 (7.96) | |
| I | 205/997 (20.56) | 18/226 (7.96) | |
| II | 335/997 (33.60) | 74/226 (32.74) | |
| III | 114/997 (11.43) | 50/226 (22.12) | |
| IV | 205/997 (20.56) | 66/226 (29.20) | |
| CLL-IPI stage | <.001 | ||
| Low | 254/718 (35.38) | 37/168 (22.02) | |
| Intermediate | 222/718 (30.92) | 50/168 (29.76) | |
| High | 179/718 (24.93) | 64/168 (38.10) | |
| Very high | 63/718 (8.77) | 17/168 (10.12) | |
| Abnormal karyotype | 423/891 (47.47) | 98/197 (49.75) | .564 |
| Complex karyotype | 180/891 (20.20) | 43/197 (21.83) | .609 |
| FISH examination | |||
| With TP53 deletion (17p) | 85/895 (9.50) | 23/210 (10.95) | .523 |
| With ATM deletion (11q) | 89/847 (10.51) | 17/203 (8.37) | .365 |
| With 13q deletion (13q) | 120/551 (21.78) | 16/137 (11.68) | .008 |
| CEP12 (+12) | 148/728 (20.33) | 30/157 (19.11) | .729 |
| With mutated IGHV | 518/766 (67.62) | 111/171 (64.91) | .495 |
| Initiate treatment within the follow-up period | 560/997 (56.17) | 177/226 (78.32) | <.001 |
| Treatment regimens | .342 | ||
| Chemotherapy | 189/555 (34.05) | 50/174 (28.74) | |
| Immunochemotherapy | 153/555 (27.57) | 56/174 (32.18) | |
| Targeted therapy | 213/555 (38.38) | 68/174 (39.08) |
| Characteristics, n/N(%) . | M protein negative (N = 997) . | M protein positive (N = 226) . | P value . |
|---|---|---|---|
| Male | 643/997 (64.49) | 155/226 (68.58) | .244 |
| Age at diagnosis, median (SD) | 59.4 (10.43) | 60.19 (10.86) | .309 |
| Age > 65 years | 284/997 (28.49) | 69/226 (30.53) | .540 |
| Lymphadenopathy | 686/987 (69.50) | 143/223 (64.13) | .118 |
| Splenomegaly | 534/987 (54.10) | 167/223 (74.89) | <.001 |
| White blood cell count ≥100 × 109/L | 98/997 (9.83) | 21/226 (9.29) | .806 |
| Hemoglobin level <110 g/L | 209/997 (20.96) | 101/226 (44.69) | <.001 |
| Platelet count <100 × 109/L | 205/997 (20.56) | 66/226 (29.20) | .005 |
| Albumin <35 g/L | 34/962 (3.53) | 42/222 (18.92) | <.001 |
| Lactate dehydrogenase ≥248 U/L | 193/941 (20.51) | 76/214 (35.51) | <.001 |
| β2MG >3.5 mg/L | 270/865 (31.21) | 115/196 (58.67) | <.001 |
| Rai stage | <.001 | ||
| 0 | 138/997 (13.84) | 18/226 (7.96) | |
| I | 205/997 (20.56) | 18/226 (7.96) | |
| II | 335/997 (33.60) | 74/226 (32.74) | |
| III | 114/997 (11.43) | 50/226 (22.12) | |
| IV | 205/997 (20.56) | 66/226 (29.20) | |
| CLL-IPI stage | <.001 | ||
| Low | 254/718 (35.38) | 37/168 (22.02) | |
| Intermediate | 222/718 (30.92) | 50/168 (29.76) | |
| High | 179/718 (24.93) | 64/168 (38.10) | |
| Very high | 63/718 (8.77) | 17/168 (10.12) | |
| Abnormal karyotype | 423/891 (47.47) | 98/197 (49.75) | .564 |
| Complex karyotype | 180/891 (20.20) | 43/197 (21.83) | .609 |
| FISH examination | |||
| With TP53 deletion (17p) | 85/895 (9.50) | 23/210 (10.95) | .523 |
| With ATM deletion (11q) | 89/847 (10.51) | 17/203 (8.37) | .365 |
| With 13q deletion (13q) | 120/551 (21.78) | 16/137 (11.68) | .008 |
| CEP12 (+12) | 148/728 (20.33) | 30/157 (19.11) | .729 |
| With mutated IGHV | 518/766 (67.62) | 111/171 (64.91) | .495 |
| Initiate treatment within the follow-up period | 560/997 (56.17) | 177/226 (78.32) | <.001 |
| Treatment regimens | .342 | ||
| Chemotherapy | 189/555 (34.05) | 50/174 (28.74) | |
| Immunochemotherapy | 153/555 (27.57) | 56/174 (32.18) | |
| Targeted therapy | 213/555 (38.38) | 68/174 (39.08) |
FISH, fluorescence in situ hybridization; SD, standard deviation.